GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
H

Heartseed 219A.T · JPY

Health Care · Tokyo Stock Exchange · 🇯🇵 Japan

Compare

2,851

+5.59%

Close of 9 Nov 2026, in JPY

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in JPY, from our data supplier.

FY2025

Revenue

¥3.03bn

FY2022FY2025

Net income

¥163.4m

FY2022FY2025

Free cash flow

¥1.05bn

FY2022FY2025

Shareholders' equity

¥7.57bn

FY2022FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022
Revenue¥3.03bn¥873.6m¥344.7m¥499.1m
Gross profit¥3.03bn¥873.6m¥344.7m¥499.1m
Research and development¥2.28bn¥1.44bn¥1.36bn¥1.57bn
Operating income¥233.3m−¥1.04bn−¥1.46bn−¥1.46bn
Net income¥163.4m−¥812.7m−¥1.47bn−¥1.41bn
Diluted earnings per share7.12-36.57-64.35-61.70

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022
Total assets¥8.14bn¥7.07bn¥5.72bn¥4.94bn
Cash and short-term investments¥7.34bn¥5.30bn¥4.59bn¥3.99bn
Total liabilities¥571.4m¥444.3m¥450.2m¥208.4m
Debt¥890,000¥5.4m¥11.6m¥31.0m
Shareholders' equity¥7.57bn¥6.62bn¥5.27bn¥4.73bn
Shares outstanding23m22m23m23m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022
Cash from operations¥1.08bn−¥1.34bn−¥797.9m−¥1.92bn
Capital spending−¥28.7m−¥14.0m−¥327.8m—
Free cash flow¥1.05bn−¥1.36bn−¥1.13bn−¥1.92bn

Latest quarters

By quarter end

Apr 2026Jan 2026Oct 2025Jul 2025Apr 2025Jan 2025Oct 2024Jul 2024
Revenue¥1.5m¥465.9m¥1.11bn—¥1.92bn—¥720.4m—
Gross profit−¥10.5m¥465.9m¥1.14bn−¥10.9m¥1.91bn−¥10.0m¥720.4m−¥10.5m
Operating income−¥546.4m−¥75.2m¥375.4m−¥1.04bn¥1.38bn−¥485.4m¥175.0m−¥493.7m
Net income−¥496.1m−¥58.2m¥349.0m−¥463.6m¥1.19bn−¥478.7m¥275.9m−¥368.4m
Diluted earnings per share-21.67-2.5415.20-20.1951.65-20.8512.41-16.57
Cash from operations——¥1.08bn—————
Capital spending——−¥28.0m—————
Free cash flow——¥1.05bn—————
Total assets¥7.04bn¥7.61bn¥8.14bn¥7.71bn¥8.08bn¥6.63bn¥7.07bn¥6.57bn
Cash and short-term investments¥6.34bn¥6.41bn¥7.34bn¥6.92bn¥7.00bn¥5.67bn¥5.30bn¥5.58bn
Debt——¥890,000¥2.0m¥3.2m¥4.3m¥4.6m¥4.8m
Shareholders' equity¥6.66bn¥7.15bn¥7.57bn¥7.20bn¥7.53bn¥6.22bn¥6.62bn¥6.10bn

Financial ratios

Data as of 18 Sept 2026

FY2025FY2024FY2023FY2022
Gross margin100.0%100.0%100.0%100.0%
Operating margin7.7%-118.9%-423.4%-292.3%
Net margin5.4%-93.0%-427.4%-283.1%
Return on equity2.2%-12.3%-28.0%-29.9%
Return on assets2.0%-11.5%-25.8%-28.6%
Free cash flow yield1.8%-2.3%——
Revenue growth246.4%153.4%-30.9%—
Earnings growth-120.1%-44.8%4.3%—
Current ratio18.48x22.70x20.60x34.55x
Debt to equity0.00x0.00x0.00x0.00x
Equity ratio93.0%93.7%92.1%95.8%
Interest coverage1711.68x-2539.86x-1956.59x-1293.08x
R&D as a share of sales75.3%165.0%394.6%314.7%
Buybacks as a share of market value-3.3%———

Growth per year

Compound annual rate

3 years5 years10 years
Revenue82.5%——

Average margins

Over each period

1 year3 years5 years10 years
Gross margin100.0%100.0%——

Valuation history

At each fiscal year end

FY2025FY2024
Price to earnings253.5-78.4
Price to sales13.773.0

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.